Data Year:

For its 2024 fiscal year, LEXICON PHARMACEUTICALS, INC., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Alan J. Main Ph.D.
Executive Vice President, Innovation and Chemical Sciences
Total Compensation $1,396,523 View details Pay Rank By Title In Biotechnology industry #139 View more
Lonnel Coats
Former Chief Executive Officer and Director
Total Compensation $3,512,773 View details Pay Rank By Title In Biotechnology industry #339 View more
Jeffrey L. Wade
Former President and Chief Financial Officer
Total Compensation $2,564,274 View details Pay Rank By Title In Biotechnology industry #191 View more
Brian T. Crum
Senior Vice President and General Counsel
Total Compensation $1,430,607 View details Pay Rank By Title In Biotechnology industry #43 View more
Craig B. Granowitz M.D., Ph.D.
Senior Vice President and Chief Medical Officer
Total Compensation $1,588,383 View details Pay Rank By Title In Biotechnology industry #205 View more
Kristen L. Alexander
Vice President, Finance and Accounting
Total Compensation $613,245 View details Pay Rank By Title In Biotechnology industry #19 View more
Thomas A. Garner
Former Senior Vice President and Chief Commercial Officer
Total Compensation $1,987,425 View details Pay Rank By Title In Biotechnology industry #174 View more
Michael S. Exton Ph.D.
Chief Executive Officer and Director
Total Compensation $2,835,589 View details Pay Rank By Title In Biotechnology industry #389 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at LEXICON PHARMACEUTICALS, INC. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. LEXICON PHARMACEUTICALS, INC. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. LEXICON PHARMACEUTICALS, INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Alan J. Main Ph.D.
Executive Vice President, Innovation and Chemical Sciences
Total Cash $581,174 Equity $801,071 Other $14,278 $1,396,523
Lonnel Coats
Former Chief Executive Officer and Director
Total Cash $438,757 Equity $3,014,509 Other $59,507 $3,512,773
Jeffrey L. Wade
Former President and Chief Financial Officer
Total Cash $485,525 Equity $1,653,035 Other $425,714 $2,564,274
Brian T. Crum
Senior Vice President and General Counsel
Total Cash $598,945 Equity $814,491 Other $17,171 $1,430,607
Craig B. Granowitz M.D., Ph.D.
Senior Vice President and Chief Medical Officer
Total Cash $701,059 Equity $871,305 Other $16,019 $1,588,383
Kristen L. Alexander
Vice President, Finance and Accounting
Total Cash $362,997 Equity $233,438 Other $16,810 $613,245
Thomas A. Garner
Former Senior Vice President and Chief Commercial Officer
Total Cash $471,032 Equity $888,717 Other $627,676 $1,987,425
Michael S. Exton Ph.D.
Chief Executive Officer and Director
Total Cash $526,326 Equity $2,308,770 Other $493 $2,835,589
For its 2024 fiscal year, LEXICON PHARMACEUTICALS, INC., listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Michael S. Exton Ph.D. CEO Pay $3,168,387 Median Employee Pay $304,524 CEO Pay Ratio 10:1
For its 2024 fiscal year, LEXICON PHARMACEUTICALS, INC., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Christopher J. Sobecki Total Cash $182,051
Diane E. Sullivan Total Cash $192,051
Ivan H. Cheung Total Cash $130,235
Judith L. Swain, M.D. Total Cash $202,953
Philippe J. Amouyal Total Cash $197,051
Raymond Debbane Total Cash $217,051
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.